Molecular classification of idiopathic pulmonary fibrosis: Personalized medicine, genetics and biomarkers

Respirology

Volumn 20, Issue 7, 2015, Pages 1010-1022

  Hambly, Nathan ^a,b,c   Shimbori, Chiko ^a,b,c   Kolb, Martin ^a,b,c  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

Author keywords

biomarker; genetics; idiopathic pulmonary fibrosis

Indexed keywords

ACETYLCYSTEINE; AZATHIOPRINE; B CELL ACTIVATING FACTOR; BIOLOGICAL MARKER; CYTOKERATIN 18; INTERLEUKIN 13 ANTIBODY; INTERSTITIAL COLLAGENASE; MATRILYSIN; MUCIN 5B; NINTEDANIB; OSTEOPONTIN; PIRFENIDONE; PLACEBO; PREDNISONE; SURFACTANT PROTEIN A; SURFACTANT PROTEIN C; SURFACTANT PROTEIN D; TELOMERASE REVERSE TRANSCRIPTASE; TOLL LIKE RECEPTOR 3; TRANSCRIPTION FACTOR RUNX2; VASCULOTROPIN; CXCL13 CHEMOKINE; CXCL13 PROTEIN, HUMAN; MMP3 PROTEIN, HUMAN; STROMELYSIN;

ADAPTIVE IMMUNITY; CD4+ T LYMPHOCYTE; DIAGNOSTIC VALUE; DISEASE CLASSIFICATION; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; FIBROGENESIS; FIBROSING ALVEOLITIS; GENE EXPRESSION; GENE MUTATION; HEREDITY; HUMAN; INFLAMMATION; MORTALITY; NONHUMAN; OCULAR ALBINISM; PATHOGENESIS; PERSONALIZED MEDICINE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; REVIEW; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; TELOMERE HOMEOSTASIS; EARLY DIAGNOSIS; FORECASTING; GENETICS; GENOMICS; IDIOPATHIC PULMONARY FIBROSIS; METABOLISM; PATHOPHYSIOLOGY; PROTEOMICS; TRENDS;

BIOMARKERS; CHEMOKINE CXCL13; EARLY DIAGNOSIS; FORECASTING; GENOMICS; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; MATRIX METALLOPROTEINASE 3; PRECISION MEDICINE; PROGNOSIS; PROTEOMICS;

EID: 84941585741     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/resp.12569     Document Type: Review

References (135)

1. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, et al., An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am. J. Respir. Crit. Care Med. 2011; 183: 788-824.
2. Fernández Pérez ER, Daniels CE, Schroeder DR, St Sauver J, Hartman TE, Bartholmai BJ, Yi ES, Ryu JH,. Incidence, prevalence, and clinical course of idiopathic pulmonary fibrosis: a population-based study. Chest 2010; 137: 129-137.
3. Ley B, Collard HR, King TE Jr,. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2011; 183: 431-440.
4. Erbes R, Schaberg T, Loddenkemper R,. Lung function tests in patients with idiopathic pulmonary fibrosis. Are they helpful for predicting outcome? Chest 1997; 111: 51-57.
5. Lederer DJ, Arcasoy SM, Wilt JS, D'Ovidio F, Sonett JR, Kawut SM,. Six-minute-walk distance predicts waiting list survival in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2006; 174: 659-664.
6. Ley B, Ryerson CJ, Vittinghoff E, Ryu JH, Tomassetti S, Lee JS, Poletti V, Buccioli M, Elicker BM, Jones KD, et al., A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann. Intern. Med. 2012; 156: 684-691.
7. du Bois RM, Weycker D, Albera C, Bradford WZ, Costabel U, Kartashov A, Lancaster L, Noble PW, Raghu G, Sahn SA, et al., Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2011; 184: 459-466.
8. Wells AU, Desai SR, Rubens MB, Goh NS, Cramer D, Nicholson AG, Colby TV, du Bois RM, Hansell DM,. Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography. Am. J. Respir. Crit. Care Med. 2003; 167: 962-969.
9. Selman M, King TE, Pardo A,. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann. Intern. Med. 2001; 134: 136-151.
10. Sisson TH, Mendez M, Choi K, Subbotina N, Courey A, Cunningham A, Dave A, Engelhardt JF, Liu X, White ES, et al., Targeted injury of type II alveolar epithelial cells induces pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2010; 181: 254-263.
11. Kasper M, Haroske G,. Alterations in the alveolar epithelium after injury leading to pulmonary fibrosis. Histol. Histopathol. 1996; 11: 463-483.
12. Morishima Y, Nomura A, Uchida Y, Noguchi Y, Sakamoto T, Ishii Y, Goto Y, Masuyama K, Zhang MJ, Hirano K, et al., Triggering the induction of myofibroblast and fibrogenesis by airway epithelial shedding. Am. J. Respir. Cell Mol. Biol. 2001; 24: 1-11.
13. Pardo A, Selman M, Kaminski N,. Approaching the degradome in idiopathic pulmonary fibrosis. Int. J. Biochem. Cell Biol. 2008; 40: 1141-1155.
14. King TE, Pardo A, Selman M,. Idiopathic pulmonary fibrosis. Lancet 2011; 378: 1949-1961.
15. Selman M, King TE, Pardo A,. American Thoracic Society; European Respiratory Society; American College of Chest Physicians. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann. Intern. Med. 2001; 134: 136-151.
16. Borensztajn K, Crestani B, Kolb M,. Idiopathic pulmonary fibrosis: from epithelial injury to biomarkers-insights from the bench side. Respiration 2013; 86: 441-452.
17. Idiopathic Pulmonary Fibrosis Clinical Research Network, Raghu G, Anstrom KJ, King TE Jr, Lasky JA, Martinez FJ,. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N. Engl. J. Med. 2012; 366: 1968-1977.
18. King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, Gorina E, Hopkins PM, Kardatzke D, Lancaster L, et al., A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N. Engl. J. Med. 2014; 370: 2083-2092.
19. Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, King TE Jr, Lancaster L, Sahn SA, Szwarcberg J, et al., Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011; 377: 1760-1769.
20. Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, Cottin V, Flaherty KR, Hansell DM, Inoue Y, et al., Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N. Engl. J. Med. 2014; 370: 2071-2082.
21. Wynn TA, Ramalingam TR,. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat. Med. 2012; 18: 1028-1040.
22. Herazo-Maya JD, Noth I, Duncan SR, Kim S, Ma SF, Tseng GC, Feingold E, Juan-Guardela BM, Richards TJ, Lussier Y, et al., Peripheral blood mononuclear cell gene expression profiles predict poor outcome in idiopathic pulmonary fibrosis. Sci Transl Med 2013; 5: 205ra136.
23. Taille C, Grootenboer-Mignot S, Boursier C, Michel L, Debray MP, Fagart J, Barrientos L, Mailleux A, Cigna N, Tubach F, et al., Identification of periplakin as a new target for autoreactivity in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2011; 183: 759-766.
24. Kahloon RA, Xue J, Bhargava A, Csizmadia E, Otterbein L, Kass DJ, Bon J, Soejima M, Levesque MC, Lindell KO, et al., Patients with idiopathic pulmonary fibrosis with antibodies to heat shock protein 70 have poor prognoses. Am. J. Respir. Crit. Care Med. 2013; 187: 768-775.
25. Xue J, Kass DJ, Bon J, Vuga L, Tan J, Csizmadia E, Otterbein L, Soejima M, Levesque MC, Gibson KF, et al., Plasma B lymphocyte stimulator and B cell differentiation in idiopathic pulmonary fibrosis patients. J. Immunol. 2013; 191: 2089-2095.
26. Boorsma CE, Draijer C, Melgert BN,. Macrophage heterogeneity in respiratory diseases. Mediators Inflamm. 2013; 769214: 1-19.
27. Song E, Ouyang N, Hörbelt M, Antus B, Wang M, Exton MS,. Influence of alternatively and classically activated macrophages on fibrogenic activities of human fibroblasts. Cell. Immunol. 2000; 204: 19-28.
28. Atabai K, Jame S, Azhar N, Kuo A, Lam M, McKleroy W, Dehart G, Rahman S, Xia DD, Melton AC, et al., Mfge8 diminishes the severity of tissue fibrosis in mice by binding and targeting collagen for uptake by macrophages. J. Clin. Invest. 2009; 119: 3713-3722.
29. Torry DJ, Richards CD, Podor TJ, Gauldie J,. Anchorage-independent colony growth of pulmonary fibroblasts derived from fibrotic human lung tissue. J. Clin. Invest. 1994; 93: 1525-1532.
30. Vancheri C, Failla M, Crimi N, Raghu G,. Idiopathic pulmonary fibrosis: a disease with similarities and links to cancer biology. Eur. Respir. J. 2010; 35: 496-504.
31. Shimbori C, Gauldie J, Kolb M,. Extracellular matrix microenvironment contributes actively to pulmonary fibrosis. Curr. Opin. Pulm. Med. 2013; 19: 446-452.
32. Selman M, Pardo A,. Revealing the pathogenic and aging-related mechanisms of the enigmatic idiopathic pulmonary fibrosis. Am J Resp Crit Care Med 2014; 189: 1161-1172.
33. Marinkovic A, Mih JD, Park JA, Liu F, Tschumperlin DJ,. Improved throughput traction microscopy reveals pivotal role for matrix stiffness in fibroblast contractility and TGF-β responsiveness. Am. J. Physiol. Lung Cell. Mol. Physiol. 2012; 303: L169-180.
34. Marinkovic A, Liu F, Tschumperlin DJ,. Matrices of physiologic stiffness potently inactivate idiopathic pulmonary fibrosis fibroblasts. Am. J. Respir. Cell Mol. Biol. 2013; 48: 422-430.
35. Pardo A, Selman M,. Role of matrix metaloproteases in idiopathic pulmonary fibrosis. Fibrogenesis Tissue Repair 2012; 5 (Suppl. 1): S9.
36. Seibold MA, Wise AL, Speer MC, Steele MP, Brown KK, Loyd JE, Fingerlin TE, Zhang W, Gudmundsson G, Groshong SD, et al., A common MUC5B promoter polymorphism and pulmonary fibrosis. N. Engl. J. Med. 2011; 364: 1503-1512.
37. Armanios MY, Chen JJ, Cogan JD, Alder JK, Ingersoll RG, Markin C, Lawson WE, Xie M, Vulto I, Phillips JA 3rd, et al., Telomerase mutations in families with idiopathic pulmonary fibrosis. N. Engl. J. Med. 2007; 356: 1317-1326.
38. Tsakiri KD, Cronkhite JT, Kuan PJ, Xing C, Raghu G, Weissler JC, Rosenblatt RL, Shay JW, Garcia CK,. Adult-onset pulmonary fibrosis caused by mutations in telomerase. Proc Natl Acad Sci USA 2007; 104: 7552-7557.
39. Stuart BD, Lee JS, Kozlitina J, Noth I, Devine MS, Glazer CS, Torres F, Kaza V, Girod CE, Jones KD, et al., Effect of telomere length on survival in patients with idiopathic pulmonary fibrosis: an observational cohort study with independent validation. Lancet Respir Med 2014; 2: 557-565.
40. O'Dwyer DN, Armstrong ME, Trujillo G, Cooke G, Keane MP, Fallon PG, Simpson AJ, Millar AB, McGrath EE, Whyte MK, et al., The toll-like receptor 3 L412F polymorphism and disease progression in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2013; 188: 1442-1450.
41. Satoh H, Kurishima K, Ishikawa H, Ohtsuka M,. Increased levels of KL-6 and subsequent mortality in patients with interstitial lung diseases. J. Intern. Med. 2006; 260: 429-434.
42. Azuma A, Nukiwa T, Tsuboi E, Suga M, Abe S, Nakata K, Taguchi Y, Nagai S, Itoh H, Ohi M, et al., Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2005; 171: 1040-1047.
43. Ando M, Miyazaki E, Ito T, Hiroshige S, Nureki SI, Ueno T, Takenaka, Fukami T, Kumamoto,. Significance of serum vascular endothelial growth factor level in patients with idiopathic pulmonary fibrosis. Lung 2010; 188: 247-252.
44. Cha SI, Ryerson CJ, Lee JS, Kukreja J, Barry SS, Jones KD, Elicker BM, Kim DS, Papa FR, Collard HR, et al., Cleaved cytokeratin-18 is a mechanistically informative biomarker in idiopathic pulmonary fibrosis. Respir. Res. 2012; 13: 105.
45. Richards TJ, Kaminski N, Baribaud F, Flavin S, Brodmerkel C, Horowitz D, Li K, Choi J, Vuga LJ, Lindell KO, et al., Peripheral blood proteins predict mortality in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2012; 185: 67-76.
46. Sidhu SS, Yuan S, Innes AL, Kerr S, Woodruff PG, Hou L, Muller SJ, Fahy JV,. Roles of epithelial cell-derived periostin in TGF-beta activation, collagen production, and collagen gel elasticity in asthma. Proc Natl Acad Sci USA 2010; 107: 14170-14175.
47. Kadota J, Mizunoe S, Mito K, Mukae H, Yoshioka S, Kawakami K, Koguchi Y, Fukushima K, Kon S, Kohno S, et al., High plasma concentrations of osteopontin in patients with interstitial pneumonia. Respir. Med. 2005; 99: 111-117.
48. Moeller A, Gilpin SE, Ask K, Cox G, Cook D, Gauldie J, Margetts PJ, Farkas L, Dobranowski J, Boylan C, et al., Circulating fibrocytes are an indicator of poor prognosis in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2009; 179: 588-594.
49. Korthagen NM, van Moorsel CH, Barlo NP, Ruven HJ, Kruit A, Heron M, van den Bosch JM, Grutters JC,. Serum and BALF YKL-40 levels are predictors of survival in idiopathic pulmonary fibrosis. Respir. Med. 2011; 105: 106-113.
50. Prasse A, Probst C, Bargagli E, Zissel G, Toews GB, Flaherty KR, Olschewski M, Rottoli P, Muller-Quernheim J,. Serum CC-chemokine ligand 18 concentration predicts outcome in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2009; 179: 717-723.
51. Vuga LJ, Tedrow JR, Pandit KV, Tan J, Kass DJ, Xue J, Chandra D, Leader JK, Gibson KF, Kaminski N, et al., C-X-C motif chemokine 13 (CXCL13) is a prognostic biomarker of idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2014; 189: 966-974.
52. Gilani SR, Vuga LJ, Lindell KO, Gibson KF, Xue J, Kaminski N, Valentine VG, Lindsay EK, George MP, Steele C, et al., CD28 down-regulation on circulating CD4 T-cells is associated with poor prognoses of patients with idiopathic pulmonary fibrosis. PLoS ONE 2010; 5: e8959.
53. Zhang Y, Kaminski N,. Biomarkers in idiopathic pulmonary fibrosis. Curr. Opin. Pulm. Med. 2012; 18: 441-446.
54. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 2001; 69: 89-95.
55. Cronkhite JT, Xing C, Raghu G, Chin KM, Torres F, Rosenblatt RL, Garcia CK,. Telomere shortening in familial and sporadic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2008; 178: 729-737.
56. Ishikawa N, Hattori N, Yokoyama A, Kohno N,. Utility of KL-6/ MUC1 in the clinical management of interstitial lung diseases. Respir Investig 2012; 50: 3-13.
57. Bandoh S, Fujita J, Ohtsuki Y, Ueda Y, Hojo S, Tokuda M, Dobashi H, Kurata N, Yoshinouchi T, Kohno N, et al., Sequential changes of KL-6 in sera of patients with interstitial pneumonia associated with poly- myositis/dermatomyositis. Ann. Rheum. Dis. 2000; 59: 257-262.
58. Hirasawa Y, Kohno N, Yokoyama A, Inoue Y, Abe M, Hiwada K,. KL-6, a human MUC1 mucin, is chemotactic for human fibroblasts. Am. J. Respir. Cell Mol. Biol. 1997; 17: 501-507.
59. Ohshimo S, Yokoyama A, Hattori N, Ishikawa N, Hirasawa Y, Kohno N,. KL-6, a human MUC1 mucin, promotes proliferation and survival of lung fibroblasts. Biochem. Biophys. Res. Commun. 2005; 338: 1845-1852.
60. Ishii H, Mukae H, Kadota J, Kaida H, Nagata T, Abe K, Matsukura S, Kohno S,. High serum concentrations of surfactant protein A in usual interstitial pneumonia compared with non-specific interstitial pneumonia. Thorax 2003; 58: 52-57.
61. Ohnishi H, Yokoyama A, Kondo K, Hamada H, Abe M, Nishimura K, Hiwada K, Kohno N,. Comparative study of KL-6, surfactant protein-A, surfactant protein-D, and monocyte chemoattractant protein-1 as serum markers for interstitial lung diseases. Am. J. Respir. Crit. Care Med. 2002; 165: 378-381.
62. Hirasawa Y, Kohno N, Yokoyama A, Kondo K, Hiwada K, Miyake M,. Natural autoantibody to MUC1 is a prognostic indicator for non-small cell lung cancer. Am. J. Respir. Crit. Care Med. 2000; 161: 589-594.
63. Inoue Y, Nishimura K, Shiode M, Akutsu H, Hamada H, Fujioka S, Fujino S, Yokoyama A, Kohno N, Hiwada K,. Evaluation of serum KL-6 levels in patients with pulmonary tuberculosis. Tuber. Lung Dis. 1995; 76: 230-233.
64. Yokoyama A, Kohno N, Hamada H, Sakatani M, Ueda E, Kondo K, Hirasawa Y, Hiwada K,. Circulating KL-6 predicts the outcome of rapidly progressive idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 1998; 158: 1680-1684.
65. Song JW, Do KH, Jang SJ, Colby TV, Han S, Kim DS,. Blood biomarkers MMP-7 and SP-A: predictors of outcome in idiopathic pulmonary fibrosis. Chest 2013; 143: 1422-1429.
66. Taniguchi H, Ebina M, Kondoh Y, Ogura T, Azuma A, Suga M, Taguchi Y, Takahashi H, Nakata K, Sato A, et al., Pirfenidone in idiopathic pulmonary fibrosis. Eur. Respir. J. 2010; 35: 821-829.
67. Goerke J,. Pulmonary surfactant: functions and molecular composition. Biochim. Biophys. Acta 1998; 1408: 79-89.
68. Tanjore H, Blackwell TS, Lawson WE,. Emerging evidence for endoplasmic reticulum stress in the pathogenesis of idiopathic pulmonary fibrosis. Am. J. Physiol. Lung Cell. Mol. Physiol. 2012; 302: L721-729.
69. Bridges JP, Wert SE, Nogee LM, Weaver TE,. Expression of a human surfactant protein C mutation associated with interstitial lung disease disrupts lung development in transgenic mice. J. Biol. Chem. 2003; 278: 52739-52746.
70. Chibbar R, Shih F, Baga M, Torlakovic E, Ramlall K, Skomro R, Cockcroft DW, Lemire EG,. Nonspecific interstitial pneumonia and usual interstitial pneumonia with mutation in surfactant protein C in familial pulmonary fibrosis. Mod. Pathol. 2004; 17: 973-980.
71. Lawson WE, Cheng DS, Degryse AL, Tanjore H, Polosukhin VV, Xu XC, Newcomb DC, Jones BR, Roldan J, Lane KB, et al., Endoplasmic reticulum stress enhances fibrotic remodeling in the lungs. Proc Natl Acad Sci USA 2011; 108: 10562-10567.
72. Selman M, Lin HM, Montano M, Jenkins AL, Estrada A, Lin Z, Wang G, DiAngelo SL, Guo X, Umstead TM, et al., Surfactant protein A and B genetic variants predispose to idiopathic pulmonary fibrosis. Hum. Genet. 2003; 113: 542-550.
73. Nogee LM, Dunbar AE 3rd, Wert SE, Askin F, Hamvas A, Whitsett JA,. A mutation in the surfactant protein C gene associated with familial interstitial lung disease. N. Engl. J. Med. 2001; 344: 573-579.
74. Lawson WE, Crossno PF, Polosukhin VV, Roldan J, Cheng DS, Lane KB, Blackwell TR, Xu C, Markin C, Ware LB, et al., Endoplasmic reticulum stress in alveolar epithelial cells is prominent in IPF: association with altered surfactant protein processing and herpesvirus infection. Am. J. Physiol. Lung Cell. Mol. Physiol. 2008; 294: L1119-11126.
75. Lawson WE, Grant SW, Ambrosini V, Womble KE, Dawson EP, Lane KB, Markin C, Renzoni E, Lympany P, Thomas AQ, et al., Genetic mutations in surfactant protein C are a rare cause of sporadic cases of IPF. Thorax 2004; 59: 977-980.
76. Maitra M, Wang Y, Gerard RD, Mendelson CR, Garcia CK,. Surfactant protein A2 mutations associated with pulmonary fibrosis lead to protein instability and endoplasmic reticulum stress. J. Biol. Chem. 2010; 285: 22103-22113.
77. Markart P, Ruppert C, Wygrecka M, Schmidt R, Korfei M, Harbach H, Theruvath I, Pison U, Seeger W, Guenther A, et al., Surfactant protein C mutations in sporadic forms of idiopathic interstitial pneumonias. Eur. Respir. J. 2007; 29: 134-137.
78. Greene KE, King TE Jr, Kuroki Y, Bucher-Bartelson B, Hunninghake GW, Newman LS, Nagae H, Mason RJ,. Serum surfactant proteins- A and -D as biomarkers in idiopathic pulmonary fibrosis. Eur. Respir. J. 2002; 19: 439-446.
79. Collard HR, Calfee CS, Wolters PJ, Song JW, Hong SB, Brady S, Ishizaka A, Jones KD, King TE Jr, Matthay MA, et al., Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis. Am. J. Physiol. Lung Cell. Mol. Physiol. 2010; 299: L3-7.
80. Ishii H, Mukae H, Kadota J, Kaida H, Nagata T, Abe K, Matsukura S, Kohno S,. High serum concentrations of surfactant protein A in usual interstitial pneumonia compared with nonspecific interstitial pneumonia. Thorax 2003; 58: 52-57.
81. Greene KE, King TE Jr, Kuroki Y, Bucher-Bartelson B, Hunninghake GW, Newman LS, Nagae H, Mason RJ,. Serum surfactant proteins-A and -D as biomarkers in idiopathic pulmonary fibrosis. Eur. Respir. J. 2002; 19: 439-446.
82. Kinder BW, Brown KK, McCormack FX, Ix JH, Kervitsky A, Schwarz MI, King TE Jr,. Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis. Chest 2009; 135: 1557-1563.
83. Takahashi H, Fujishima T, Koba H, Murakami S, Kurokawa K, Shibuya Y, Shiratori M, Kuroki Y, Abe S,. Serum surfactant proteins A and D as prognostic factors in idiopathic pulmonary fibrosis and their relationship to disease extent. Am. J. Respir. Crit. Care Med. 2000; 162: 1109-1114.
84. Alder JK, Chen JJ, Lancaster L, Danoff S, Su SC, Cogan JD, Vulto I, Xie M, Qi X, Tuder RM, et al., Short telomeres are a risk factor for idiopathic pulmonary fibrosis. Proc Natl Acad Sci USA 2008; 105: 13051-13056.
85. Rode L, Bojesen SE, Weischer M, Vestbo J, Nordestgaard BG,. Short telomere length, lung function and chronic obstructive pulmonary disease in 46,396 individuals. Thorax 2013; 68: 429-435.
86. Ley B, Brown KK, Collard HR,. Molecular biomarkers in idiopathic pulmonary fibrosis. Am. J. Physiol. Lung Cell. Mol. Physiol. 2014; 307: L681-691.
87. Zhang Y, Noth I, Garcia JG, Kaminski N,. A variant in the promoter of MUC5B and idiopathic pulmonary fibrosis. N. Engl. J. Med. 2011; 364: 1576-1577.
88. Stock CJ, Sato H, Fonseca C, Banya WA, Molyneaux PL, Adamali H, Russell AM, Denton CP, Abraham DJ, Hansell DM, et al., Mucin 5B promoter polymorphism is associated with idiopathic pulmonary fibrosis but not with development of lung fibrosis in systemic sclerosis or sarcoidosis. Thorax 2013; 68: 436-441.
89. Borie R, Crestani B, Dieude P, Nunes H, Allanore Y, Kannengiesser C, Airo P, Matucci-Cerinic M, Wallaert B, Israel-Biet D, et al., The MUC5B variant is associated with idiopathic pulmonary fibrosis but not with systemic sclerosis interstitial lung disease in the European Caucasian population. PLoS ONE 2013; 8: e70621.
90. Noth I, Zhang Y, Ma SF, Flores C, Barber M, Huang Y, Broderick SM, Wade MS, Hysi P, Scuirba J, et al., Genetic variants associated with idiopathic pulmonary fibrosis susceptibility and mortality: a genome-wide association study. Lancet Respir Med 2013; 1: 309-317.
91. Fingerlin TE, Murphy E, Zhang W, Peljto AL, Brown KK, Steele MP, Loyd JE, Cosgrove GP, Lynch D, Groshong S, et al., Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis. Nat. Genet. 2013; 45: 613-620.
92. Putman RK, Rosas IO, Hunninghake GM,. Genetics and early detection in idiopathic pulmonary fibrosis. Am J Resp Crit Care Med 2014; 189: 770-778.
93. Tsushima K, Sone S, Yoshikawa S, Yokoyama T, Suzuki T, Kubo K,. The radiological patterns of interstitial change at an early phase: over a 4-year follow-up. Respir. Med. 2010; 104: 1712-1721.
94. Sverzellati N, Guerci L, Randi G, Calabro E, La Vecchia C, Marchiano A, Pesci A, Zompatori M, Pastorino U,. Interstitial lung diseases in a lung cancer screening trial. Eur. Respir. J. 2011; 38: 392-400.
95. Jin GY, Lynch D, Chawla A, Garg K, Tammemagi MC, Sahin H, Misumi S, Kwon KS,. Interstitial lung abnormalities in a CT lung cancer screening population: prevalence and progression rate. Radiology 2013; 268: 563-571.
96. Hunninghake GM, Hatabu H, Okajima Y, Gao W, Dupuis J, Latourelle JC, Nishino M, Araki T, Zazueta OE, Kurugol S, et al., MUC5B promoter polymorphism and interstitial lung abnormalities. N. Engl. J. Med. 2013; 368: 2192-2200.
97. Peljto AL, Zhang Y, Fingerlin TE, Ma SF, Garcia JG, Richards TJ, Silveira LJ, Lindell KO, Steele MP, Loyd JE, et al., Association between the MUC5B promoter polymorphism and survival in patients with idiopathic pulmonary fibrosis. JAMA 2013; 309: 2232-2239.
98. Fletcher AA, Evans CM,. Regulation of microbial populations and immune functions by Muc5b. Ann Am Thorac Soc 2014; 11: S80. doi: 10.1513/AnnalsATS.201308-263MG.
99. Molyneaux PL, Cox MJ, Willis-Owen SAG, Mallia P, Russell KE, Russell AM, Murphy E, Johnston SL, Schwartz DA, Wells AU, et al., The role of bacteria in the pathogenesis and progression of idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2014; 190: 906-913.
100. Monacci WT, Merrill MJ, Oldfield EH,. Expression of vascular permeability factor/vascular endothelial growth factor in normal rat tissues. Am. J. Physiol. 1993; 264: C995-1002.
101. Hanumegowda C, Farkas L, Kolb M,. Angiogenesis in pulmonary fibrosis. Too much or not enough? Chest 2012; 142: 200-207.
102. Koyama S, Sato E, Haniuda M, Numanami H, Nagai S, Izumi T,. Decreased level of vascular endothelial growth factor in bronchoalveolar lavage fluid of normal smokers and patients with pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2002; 166: 382-385.
103. Meyer KC, Cardoni A, Xiang ZZ,. Vascular endothelial growth factor in bronchoalveolar lavage from normal subjects and patients with diffuse parenchymal lung disease. J. Lab. Clin. Med. 2000; 135: 332-338.
104. Leers MP, Kolgen W, Bjorklund V, Bergman T, Tribbick G, Persson B, Bjorklund P, Ramaekers FC, Bjorklund B, Nap M, et al., Immunocytochemical detection and mapping of a cytokeratin 18 neo-epitope exposed during early apoptosis. J. Pathol. 1999; 187: 567-572.
105. Pardo A, Selman M,. Matrix metalloproteinases in aberrant tissue remodeling. Proc. Am. Thorac. Soc. 2006; 3: 383-388.
106. Selman M, Pardo A, Barrera L, Estrada A, Watson SR, Wilson K, Aziz N, Kaminski N, Zlotnik A,. Gene expression profiles distinguish idiopathic pulmonary fibrosis from hypersensitivity pneumonitis. Am. J. Respir. Crit. Care Med. 2006; 173: 188-198.
107. Rosas IO, Richards TJ, Konishi K, Zhang Y, Gibson K, Lokshin AE, Lindell KO, Cisneros J, Macdonald SD, Pardo A, et al., MMP1 and MMP7 as potential peripheral blood biomarkers in idiopathic pulmonary fibrosis. PLoS Med. 2008; 5: e93.
108. Zuo F, Kaminski N, Eugui E, Allard J, Yakhini Z, Ben-Dor A, Lollini L, Morris D, Kim Y, DeLustro B, et al., Gene expression analysis reveals matrilysin as a key regulator of pulmonary fibrosis in mice and humans. Proc Natl Acad Sci USA 2002; 99: 6292-6297.
109. Vuorinen K, Myllärniemi M, Lammi L, Piirilä P, Rytilä P, Salmenkivi K, Kinnula VL,. Elevated matrilysin levels in bronchoalveolar lavage fluid do not distinguish idiopathic pulmonary fibrosis from other interstitial lung diseases. APMIS 2007; 115: 969-975.
110. Huh JW, Kim DS, Oh YM, Shim TS, Lim CM, Lee SD, Koh Y, Kim WS, Kim WD, Kim KR,. Is metalloproteinase-7 specific for idiopathic pulmonary fibrosis? Chest 2008; 133: 1101-1106.
111. Okamoto M, Hoshino T, Kitasato Y, Sakazaki Y, Kawayama T, Fujimoto K, Ohshima K, Shiraishi H, Uchida M, Ono J, et al., Periostin, a matrix protein, is a novel biomarker for idiopathic interstitial pneumonias. Eur. Respir. J. 2011; 37: 1119-1127.
112. Naik PK, Bozyk PD, Bentley JK, Popova AP, Birch CM, Wilke CA, Fry CD, White ES, Sisson TH, Tayob N, et al., Periostin promotes fibrosis and predicts progression in patients with idiopathic pulmonary fibrosis. Am. J. Physiol. Lung Cell. Mol. Physiol. 2012; 303: L1046-1056.
113. Denhardt DT, Noda M, O'Regan AW, Pavlin D, Berman JS,. Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival. J. Clin. Invest. 2001; 107: 1055-1061.
114. O'Regan A, Berman JS,. Osteopontin: a key cytokine in cell- mediated and granulomatous inflammation. Int. J. Exp. Pathol. 2000; 81: 373-390.
115. Takahashi F, Takahashi K, Okazaki T, Maeda K, Ienaga H, Maeda M, Kon S, Uede T, Fukuchi Y,. Role of osteopontin in the pathogenesis of bleomycin-induced pulmonary fibrosis. Am. J. Respir. Cell Mol. Biol. 2001; 24: 264-271.
116. Pardo A, Gibson K, Cisneros J, Richards TJ, Yang Y, Becerril C, Yousem S, Herrera I, Ruiz V, Selman M, et al., Up-regulation and profibrotic role of osteopontin in human idiopathic pulmonary fibrosis. PLoS Med. 2005; 2: e251.
117. Agnihotri R, Crawford HC, Haro H, Matrisian LM, Havrda MC, Liaw L,. Osteopontin, a novel substrate for matrix metalloproteinase-3 (stromelysin-1) and matrix metalloproteinase-7 (matrilysin). J. Biol. Chem. 2001; 276: 28261-28267.
118. Bellini A, Mattoli S,. The role of the fibrocyte, a bone marrow-derived mesenchymal progenitor, in reactive and reparative fibroses. Lab. Invest. 2007; 87: 858-870.
119. Moore BB, Kolodsick JE, Thannickal VJ, Cooke K, Moore TA, Hogaboam C, Wilke CA, Toews GB,. CCR2-mediated recruitment of fibrocytes to the alveolar space after fibrotic injury. Am. J. Pathol. 2005; 166: 675-684.
120. Andersson-Sjöland A, de Alba CG, Nihlberg K, Becerril C, Ramírez R, Pardo A, Westergren-Thorsson G, Selman M,. Fibrocytes are a potential source of lung fibroblasts in idiopathic pulmonary fibrosis. Int. J. Biochem. Cell Biol. 2008; 40: 2129-2140.
121. Trimble A, Gochuico BR, Markello TC, Fischer R, Gahl WA, Lee JK, Kim Y, Burdick MD, Strieter RM, Mehrad B,. Circulating fibrocytes as biomarker of prognosis in Hermansky-Pudlak syndrome. Am. J. Respir. Crit. Care Med. 2014; 190: 1395-1401.
122. Kruit A, Grutters JC, Ruven HJ, van Moorsel CC, van den Bosch JM,. A CHI3L1 gene polymorphism is associated with serum levels of YKL-40, a novel sarcoidosis marker. Respir. Med. 2007; 101: 1563-1571.
123. Létuvé S, Kozhich A, Arouche N, Grandsaigne M, Reed J, Dombret MC, Kiener PA, Aubier M, Coyle AJ, Pretolani M,. YKL-40 is elevated in patients with chronic obstructive pulmonary disease and activates alveolar macrophages. J. Immunol. 2008; 181: 5167-5173.
124. Chupp GL, Lee CG, Jarjour N, Shim YM, Holm CT, He S, Dziura JD, Reed J, Coyle AJ, Kiener P, et al., A chitinase-like protein in the lung and circulation of patients with severe asthma. N. Engl. J. Med. 2007; 357: 2016-2027.
125. Ober C, Chupp GL,. The chitinase and chitinase-like proteins: a review of genetic and functional studies in asthma and immune-mediated diseases. Curr. Opin. Allergy Clin. Immunol. 2009; 9: 401-408.
126. Lee CG, Da Silva CA, Dela Cruz CS, Ahangari F, Ma B, Kang MJ, He CH, Takyar S, Elias JA,. Role of chitin and chitinase/chitinase-like proteins in inflammation, tissue remodeling, and injury. Annu. Rev. Physiol. 2011; 73: 479-501.
127. Furuhashi K, Suda T, Nakamura Y, Inui N, Hashimoto D, Miwa S, Hayakawa H, Kusagaya H, Nakano Y, Nakamura H, et al., Increased expression of YKL-40, a chitinase-like protein, in serum and lung of patients with idiopathic pulmonary fibrosis. Respir. Med. 2010; 104: 1204-1210.
128. Kodera M, Hasegawa M, Komura K, Yanaba K, Takehara K, Sato S,. Serum pulmonary and activation-regulated chemokine/CCL18 levels in patients with systemic sclerosis: a sensitive indicator of active pulmonary fibrosis. Arthritis Rheum. 2005; 52: 2889-2896.
129. Prasse A, Pechkovsky DV, Toews GB, Jungraithmayr W, Kollert F, Goldmann T, Vollmer E, Muller-Quernheim J, Zissel G,. A vicious circle of alveolar macrophages and fibroblasts perpetuates pulmonary fibrosis via CCL18. Am. J. Respir. Crit. Care Med. 2006; 173: 781-792.
130. Prasse A, Pechkovsky DV, Toews GB, Schafer M, Eggeling S, Ludwig C, Germann M, Kollert F, Zissel G, Muller-Quernheim J,. CCL18 as an indicator of pulmonary fibrotic activity in idiopathic interstitial pneumonias and systemic sclerosis. Arthritis Rheum. 2007; 56: 1685-1693.
131. Parra ER, Kairalla RA, Ribeiro de Carvalho CR, Eher E, Capelozzi VL,. Inflammatory cell phenotyping of the pulmonary interstitium in idiopathic interstitial pneumonia. Respiration 2007; 74: 159-169.
132. Daniil Z, Kitsanta P, Kapotsis G, Mathioudaki M, Kollintza A, Karatza M, Milic-Emili J, Roussos C, Papiris SA,. CD8+ T lymphocytes in lung tissue from patients with idiopathic pulmonary fibrosis. Respir. Res. 2005; 6: 81.
133. Konishi K, Gibson KF, Lindell KO, Richards TJ, Zhang Y, Dhir R, Bisceglia M, Gilbert S, Yousem SA, Song JW, et al., Gene expression profiles of acute exacerbations of idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2009; 180: 167-175.
134. Boon K, Bailey NW, Yang J, Steel MP, Groshong S, Kervitsky D, Brown KK, Schwarz MI, Schwartz DA,. Molecular phenotypes distinguish patients with relatively stable from progressive idiopathic pulmonary fibrosis. PLoS ONE 2009; 4: e5134. doi: 10.1371/journal.pone.0005134.
135. DePianto DJ, Chandriani S, Abbas AR, Jia G, N'Diaye EN, Caplazi P, Kauder SE, Biswas S, Karnik SK, Ha C, et al., Heterogeneous gene expression signatures correspond to distinct lung pathologies and biomarkers of disease severity in idiopathic pulmonary fibrosis. Thorax 2015; 70: 48-56.